중동 및 아프리카 동결건조 주사제 시장, 포장(바이알, 듀얼 챔버 주사기, 듀얼 챔버 카트리지 및 기타), 약물 종류(항감염제, 항암제, 이뇨제, 양성자 펌프 억제제, 마취제, 항응고제, NSAID, 코르티코스테로이드 및 기타), 형태(분말 및 액체), 적응증(종양학, 자가면역 질환, 호르몬 장애, 호흡기 질환, 위장 장애, 피부과 질환, 안과 질환 및 기타), 투여 경로(정맥 주사/주입, 근육 주사 및 기타), 최종 사용자(병원, 진료소, 가정 의료 및 기타), 유통 채널(직접 입찰, 소매 판매 및 기타), 국가(사우디 아라비아, 남아프리카 공화국, UAE, 이스라엘, 쿠웨이트, 이집트 및 중동 및 아프리카의 나머지 지역) 산업 동향 및 2028년까지의 예측.
시장 분석 및 통찰력: 중동 및 아프리카 동결건조 주사제 시장
동결건조 주사제 시장은 2021년에서 2028년까지의 예측 기간 동안 시장 성장을 이룰 것으로 예상됩니다. Data Bridge Market Research는 시장이 2021년에서 2028년까지의 예측 기간 동안 4.2%의 CAGR로 성장하고 있으며 2028년까지 2억 814만 달러에 도달할 것으로 예상한다고 분석합니다. 전 세계적으로 만성 건강 문제가 증가함에 따라 동결건조 주사제 시장 수요가 증가할 것으로 예상됩니다.
동결 건조는 동결 건조의 또 다른 용어입니다. 진공 상태에서 용액을 동결시키고 증발시켜 용매에서 고체 물질을 분리하는 기술입니다. 동결 건조 제품은 기존 약물보다 유통 기한이 긴 것으로 간주되어 선호됩니다. 생물학, 단백질, 항체 미생물, 비경구, 혈장, 효소, 진단 시약, 백신 및 건강 보조 식품의 보호는 일반적으로 동결 건조를 통해 수행됩니다. 일부 불안정한 벌크 성분을 안정적으로 유지하려면 멸균 주사제의 동결 건조가 필요합니다.
동결건조 주사제에 대한 기술적 진보가 증가함에 따라 동결건조 주사제 시장 수요를 촉진하는 원동력이 될 것으로 예상됩니다. 동결건조 약물과 포장 유형에 대한 제품 리콜 건수가 증가함에 따라 동결건조 주사제 시장이 제약을 받을 것으로 예상됩니다. 동결건조 약물에 대한 규제 승인이 증가함에 따라 동결건조 주사제 시장 수요를 촉진하는 기회가 될 것으로 예상됩니다. 비경구용 제품용 동결건조 바이알을 제조하는 것과 관련된 요인이 동결건조 주사제 시장 수요에 도전할 것으로 예상됩니다.
The lyophilized injectable drugs market report provides details of market share, new developments, and product pipeline analysis, impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, product approvals, strategic decisions, product launches, geographic expansions, and technological innovations in the market. To understand the analysis and the lyophilized injectable drugs market scenario contact Data Bridge Market Research for an Analyst Brief, our team will help you create a revenue impact solution to achieve your desired goal.
Lyophilized Injectable Drugs Market scope and market size
The lyophilized injectable drugs market is categorized into seven notable segments which are based on the packaging, drug class, form, indication, route of administration, end user and distribution channel. The growth among segments helps you analyse niche pockets of growth and strategies to approach the market and determine your core application areas and the difference in your target markets.
- On the basis of packaging, the lyophilized injectable drugs market is segmented into vials, dual-chamber syringes, dual-chamber cartridges and others. In 2021, vials segment is expected to dominate the lyophilized injectable drugs market because most of the lyophilized injectable drugs are packaged in vials, so it is influential as well as growing in the market.
- On the basis of drug class, the lyophilized injectable drugs market is segmented into anti-infective, antineoplastic, diuretics, proton pump inhibitor, anesthetic, anticoagulant, NSAID’s, corticosteroids and others. In 2021, anti-infective segment is expected to dominate the lyophilized injectable drugs market because of the increased demand for the antibiotics and antiviral drugs across globe.
- On the basis of form, the lyophilized injectable drugs market is segmented into powder and liquid. In 2021, powder segment is expected to dominate the lyophilized injectable drugs market because of its easy and safe storage plus transportation across globe.
- On the basis of indication, the lyophilized injectable drugs market is segmented into oncology, autoimmune diseases, hormonal disorders, respiratory diseases, gastrointestinal disorders, dermatological disorders, ophthalmic diseases and others. In 2021, oncology segment is expected to dominate the lyophilized injectable drugs market because of the availability of increased number of lyophilized injectable drugs for oncology.
- On the basis of route of administration, the lyophilized injectable drugs market is segmented into intravenous/infusion, intramuscular and others. In 2021, intravenous/infusion segment is expected to dominate the lyophilized injectable drugs market because of the 100% bioavailability of the drug via this route of administration.
- 최종 사용자를 기준으로 동결건조 주사제 시장은 병원, 진료소, 가정 의료 및 기타로 세분화됩니다. 2021년에는 병원 부문이 고급 장비를 구매할 수 있는 병원의 재정적 능력과 이를 관리할 훈련된 전문가의 존재로 인해 동결건조 주사제 시장을 지배할 것으로 예상됩니다.
- 유통 채널을 기준으로 동결건조 주사제 시장은 직접 입찰, 소매 판매 및 기타로 세분화됩니다. 2021년에는 직접 입찰 부문이 동결건조 주사제 시장을 지배할 것으로 예상되는데, 대부분의 서비스 제공업체가 제조업체로부터 동결건조 주사제를 구매하고 직접 판매 수익이 더 높은 것으로 나타났기 때문에 시장에 영향을 미치고 성장하고 있기 때문입니다.
중동 및 아프리카 동결건조 주사제 시장 국가 수준 분석
중동 및 아프리카 동결건조 주사제 시장을 분석하고, 위에 언급된 대로 국가, 포장, 약물 종류, 형태, 적응증, 투여 경로, 최종 사용자 및 유통 채널별로 시장 규모 정보를 제공합니다.
중동 및 아프리카 동결건조 주사제 시장에서 다루는 국가는 사우디아라비아, 남아프리카공화국, UAE, 이스라엘, 쿠웨이트, 이집트와 기타 중동 및 아프리카 국가입니다.
사우디아라비아는 주요 시장 참여자들의 존재와 해당 지역의 기술 발전 증가로 인해 중동 및 아프리카 동결건조 주사제 시장을 주도할 것으로 예상됩니다.
보고서의 국가 섹션은 또한 개별 시장 영향 요인과 국내 시장의 현재 및 미래 트렌드에 영향을 미치는 규제 변화를 제공합니다. 신규 판매, 교체 판매, 국가 인구 통계, 규제 조치 및 수출입 관세와 같은 데이터 포인트는 개별 국가의 시장 시나리오를 예측하는 데 사용되는 주요 포인터 중 일부입니다. 또한 중동 및 아프리카 브랜드의 존재 및 가용성과 지역 및 국내 브랜드와의 대규모 또는 희소한 경쟁으로 인해 직면한 과제, 판매 채널의 영향이 국가 데이터에 대한 예측 분석을 제공하는 동안 고려됩니다.
제조업체의 신제품 출시로 동결건조 주사제 시장의 참여자들에게 새로운 기회가 창출되고 있습니다.
동결건조 주사제 시장은 또한 동결건조 주사제 시장 판매, 동결건조 주사제 시장 발전의 영향, 동결건조 주사제 시장에 대한 지원과 함께 규제 시나리오의 변화와 함께 모든 국가에 대한 자세한 시장 분석을 제공합니다. 데이터는 2010년부터 2019년까지의 과거 기간에 대해 제공됩니다.
경쟁 환경 및 동결건조 주사제 시장 점유율 분석
동결건조 주사제 시장 경쟁 구도는 경쟁자별 세부 정보를 제공합니다. 포함된 세부 정보는 회사 개요, 회사 재무, 창출된 수익, 시장 잠재력, 연구 개발 투자, 새로운 시장 이니셔티브, 생산 현장 및 시설, 회사의 강점과 약점, 제품 출시, 제품 시험 파이프라인, 제품 승인, 특허, 제품 폭과 폭, 응용 분야 우세, 기술 수명선 곡선입니다. 위에 제공된 데이터 포인트는 중동 및 아프리카 동결건조 주사제 시장과 관련된 회사의 초점에만 관련이 있습니다.
중동 및 아프리카 동결건조 주사제 시장 보고서에 포함된 주요 회사는 Genex Pharma, Aristopharma Ltd., Pfizer Inc., Viatris Inc., Gilead Sciences, Inc., Jubilant Generics Limited – A Jubilant Pharma Company, Novartis AG, Otsuka America Pharmaceutical, Inc., Zydus Cadila, Cipla Inc., Merck Sharp & Dohme Corp., Merck & Co., Inc.의 자회사, Sanofi, Celon Laboratories Pvt. Ltd., Baxter 등입니다. DBMR 분석가는 경쟁 우위를 이해하고 각 경쟁사에 대한 경쟁 분석을 별도로 제공합니다.
또한 전 세계 여러 회사에서 많은 계약과 협정을 체결하면서 동결건조 주사제 시장도 가속화되고 있습니다.
- 2019년 11월, Pfizer, Inc.는 Upjohn이라는 사업부가 Mylan NV와 결합되어 Viatris Inc.라는 새로운 회사를 만들었다고 발표했습니다. 이 회사의 사업부와 Mylan NV의 결합으로 제품 포트폴리오가 확대되어 시장에서 제품 수요가 증가했습니다.
시장 참여자들의 협력, 합작투자 및 기타 전략은 동결건조 주사제 시장에서 회사 시장을 확대하고 있으며, 이를 통해 조직이 동결건조 주사제 시장에 대한 제공 서비스를 개선하는 데에도 도움이 됩니다.
SKU-
세계 최초의 시장 정보 클라우드 보고서에 온라인으로 접속하세요
- 대화형 데이터 분석 대시보드
- 높은 성장 잠재력 기회를 위한 회사 분석 대시보드
- 사용자 정의 및 질의를 위한 리서치 분석가 액세스
- 대화형 대시보드를 통한 경쟁자 분석
- 최신 뉴스, 업데이트 및 추세 분석
- 포괄적인 경쟁자 추적을 위한 벤치마크 분석의 힘 활용
목차
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
1.4 LIMITATIONS
1.5 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 MARKETS COVERED
2.2 GEOGRAPHICAL SCOPE
2.3 YEARS CONSIDERED FOR THE STUDY
2.4 CURRENCY AND PRICING
2.5 DBMR TRIPOD DATA VALIDATION MODEL
2.6 MULTIVARIATE MODELLING
2.7 PACKAGING LIFELINE CURVE
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS
2.9 DBMR MARKET POSITION GRID
2.1 VENDOR SHARE ANALYSIS
2.11 MARKET END USER COVERAGE GRID
2.12 SECONDARY SOURCES
2.13 ASSUMPTIONS
3 EXECUTIVE SUMMARY
4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: REGULATORY FRAMEWORK
5 EPIDEMIOLOGY
6 MARKET OVERVIEW
6.1 DRIVERS
6.1.1 RISE IN CHRONIC HEALTH CONDITIONS
6.1.2 SAFE TRANSIT AND STORAGE OF THESE SUBSTANCES UNTIL THEIR END-USE
6.1.3 INCREASE IN GERIATRIC POPULATION WITH CHRONIC DISEASES
6.1.4 EXPANSION OF PIPELINE OF LYOPHILIZED INJECTABLE DRUGS
6.1.5 TECHNOLOGICAL ADVANCEMENTS
6.2 RESTRAINTS
6.2.1 RISK OF NEEDLESTICK INJURIES
6.2.2 INCREASE IN NUMBER OF PRODUCT RECALLS FOR LYOPHILIZED DRUGS AND PACKAGING TYPE
6.3 OPPORTUNITIES
6.3.1 RISE IN REGULATORY APPROVALS FOR LYOPHILIZED DRUGS
6.3.2 STRATEGIC INITIATIVES OF KEY MARKET PLAYERS
6.3.3 QUALITY CONCERNS
6.4 CHALLENGES
6.4.1 CHALLENGES ASSOCIATED WITH MANUFACTURING LYOPHILIZED VIALS FOR PARENTERAL PRODUCTS
6.4.2 TIME-CONSUMING PROCESS AND HIGH COST
7 IMPACT OF COVID-19 ON THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
7.1 IMPACT ON PRICE
7.2 IMPACT IN DEMAND
7.3 IMPACT ON SUPPLY
7.4 STRATEGIC INITIATIVE
7.5 CONCLUSION
8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING
8.1 OVERVIEW
8.2 VIALS
8.3 DUAL-CHAMBER SYRINGES
8.4 DUAL-CHAMBER CARTRIDGES
8.5 OTHERS
9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS
9.1 OVERVIEW
9.2 ANTI-INFECTIVE’S
9.2.1 ANTIBIOTICS
9.2.1.1 Azithromycin
9.2.1.2 Doxycycline
9.2.1.3 Vancomycin
9.2.1.4 Polymyxin B
9.2.1.5 Piperacillin
9.2.1.6 Tazobactam
9.2.1.7 Others
9.2.2 ANTIFUNGAL
9.2.2.1 Mycamine
9.2.2.2 Caspofungin Acetate
9.2.2.3 Isavuconazonium Sulfate
9.2.2.4 Amphotericin
9.2.2.5 Others
9.2.3 ANTIVIRAL
9.2.3.1 Acyclovir
9.2.3.2 Ganciclovir
9.2.3.3 Remdesivir
9.2.3.4 Others
9.2.4 OTHERS
9.3 ANTINEOPLASTIC
9.3.1 METHOTREXATE
9.3.2 GEMCITABINE
9.3.3 CYTARABINE
9.3.4 FLUDARABINE
9.3.5 DOXORUBICIN
9.3.6 OXALIPLATIN
9.3.7 ZOLEDRONIC ACID
9.3.8 OTHERS
9.4 DIURETICS
9.4.1 CHLOROTHIAZIDE
9.4.2 ETHACRYNIC ACID
9.4.3 ACETAZOLAMIDE
9.4.4 OTHERS
9.5 PROTON PUMP INHIBITOR
9.5.1 ESOMEPRAZOLE SODIUM
9.5.2 PANTOPRAZOLE SODIUM
9.5.3 OMEPRAZOLE
9.5.4 OTHERS
9.6 ANESTHETIC
9.6.1 VECURONIUM BROMIDE
9.6.2 SODIUM THIOPENTAL
9.6.3 LIDOCAINE
9.6.4 OTHERS
9.7 ANTICOAGULANT
9.7.1 COUMADIN
9.7.2 UROKINASE
9.7.3 ANTITHROMBIN (RECOMBINANT)
9.7.4 APIXABAN
9.7.5 RIVAROXABAN
9.7.6 OTHERS
9.8 NSAID’S
9.8.1 INDOMETHACIN
9.8.2 IBUPROFEN
9.8.3 DICLOFENAC
9.8.4 KETOROLAC
9.8.5 OTHERS
9.9 CORTICOSTEROIDS
9.9.1 HYDROCORTISONE
9.9.2 METHYLPREDNISOLONE
9.9.3 OTHERS
9.1 OTHERS
10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM
10.1 OVERVIEW
10.2 POWDER
10.3 LIQUID
11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION
11.1 OVERVIEW
11.2 ONCOLOGY
11.3 AUTOIMMUNE DISEASES
11.4 HORMONAL DISORDERS
11.5 RESPIRATORY DISEASES
11.6 GASTROINTESTINAL DISORDERS
11.7 DERMATOLOGICAL DISORDERS
11.8 OPHTHALMIC DISEASES
11.9 OTHERS
12 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION
12.1 OVERVIEW
12.2 INTRAVENOUS/INFUSION
12.3 INTRAMUSCULAR
12.4 OTHERS
13 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER
13.1 OVERVIEW
13.2 HOSPITAL
13.3 CLINICS
13.4 HOME HEALTHCARE
13.5 OTHERS
14 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL
14.1 OVERVIEW
14.2 DIRECT TENDERS
14.3 RETAIL SALES
14.4 OTHERS
15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION
15.1 MIDDLE EAST & AFRICA
15.1.1 SOUTH AFRICA
15.1.2 SAUDI ARABIA
15.1.3 U.A.E.
15.1.4 EGYPT
15.1.5 KUWAIT
15.1.6 ISRAEL
15.1.7 REST OF MIDDLE EAST & AFRICA
16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY LANDSCAPE
16.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA
17 SWOT ANALYSIS
18 COMPANY PROFILE
18.1 PFIZER INC.
18.1.1 COMPANY SNAPSHOT
18.1.2 REVENUE ANALYSIS
18.1.3 COMPANY SHARE ANALYSIS
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENT
18.2 FRESENIUS KABI USA (A SUBSIDIARY OF FRESENIUS KABI AG)
18.2.1 COMPANY SNAPSHOT
18.2.2 REVENUE ANALYSIS
18.2.3 COMPANY SHARE ANALYSIS
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 CIPLA INC.
18.3.1 COMPANY SNAPSHOT
18.3.2 REVENUE ANALYSIS
18.3.3 COMPANY SHARE ANALYSIS
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENT
18.4 NOVARTIS AG
18.4.1 COMPANY SNAPSHOT
18.4.2 REVENUE ANALYSIS
18.4.3 COMPANY SHARE ANALYSIS
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENT
18.5 MERCK SHARP & DOHME CORP., A SUBSIDIARY OF MERCK & CO., INC.
18.5.1 COMPANY SNAPSHOT
18.5.2 REVENUE ANALYSIS
18.5.3 PRODUCT PORTFOLIO
18.5.4 RECENT DEVELOPMENT
18.6 BAXTER
18.6.1 COMPANY SNAPSHOT
18.6.2 REVENUE ANALYSIS
18.6.3 PRODUCT PORTFOLIO
18.6.4 RECENT DEVELOPMENTS
18.7 ZYDUS CADILA
18.7.1 COMPANY SNAPSHOT
18.7.2 REVENUE ANALYSIS
18.7.3 PRODUCT PORTFOLIO
18.7.4 RECENT DEVELOPMENT
18.8 AFFY PHARMA PVT LTD.
18.8.1 COMPANY SNAPSHOT
18.8.2 PRODUCT PORTFOLIO
18.8.3 RECENT DEVELOPMENT
18.9 AMNEAL PHARMACEUTICALS LLC
18.9.1 COMPANY SNAPSHOT
18.9.2 REVENUE ANALYSIS
18.9.3 PRODUCT PORTFOLIO
18.9.4 RECENT DEVELOPMENTS
18.1 ARISTOPHARMA LTD.
18.10.1 COMPANY SNAPSHOT
18.10.2 PRODUCT PORTFOLIO
18.10.3 RECENT DEVELOPMENT
18.11 ASTELLAS PHARMA US, INC. (A SUBSIDIARY OF ASTELLAS PHARMA INC.)
18.11.1 COMPANY SNAPSHOT
18.11.2 REVENUE ANALYSIS
18.11.3 PRODUCT PORTFOLIO
18.11.4 RECENT DEVELOPMENTS
18.12 AUROMEDICS PHARMA LLC (A SUBSIDIARY OF AUROBINDO PHARMA)
18.12.1 COMPANY SNAPSHOT
18.12.2 REVENUE ANALYSIS
18.12.3 PRODUCT PORTFOLIO
18.12.4 RECENT DEVELOPMENTS
18.13 CELON LABORATORIES PVT.LTD.
18.13.1 COMPANY SNAPSHOT
18.13.2 PRODUCT PORTFOLIO
18.13.3 RECENT DEVELOPMENT
18.14 CIRONDRUGS
18.14.1 COMPANY SNAPSHOT
18.14.2 PRODUCT PORTFOLIO
18.14.3 RECENT DEVELOPMENT
18.15 GENEX PHARMA
18.15.1 COMPANY SNAPSHOT
18.15.2 PRODUCT PORTFOLIO
18.15.3 RECENT DEVELOPMENT
18.16 GILEAD SCIENCES, INC.
18.16.1 COMPANY SNAPSHOT
18.16.2 REVENUE ANALYSIS
18.16.3 PRODUCT PORTFOLIO
18.16.4 RECENT DEVELOPMENTS
18.17 JUBILANT GENERICS LIMITED – A JUBILANT PHARMA COMPANY
18.17.1 COMPANY SNAPSHOT
18.17.2 REVENUE ANALYSIS
18.17.3 PRODUCT PORTFOLIO
18.17.4 RECENT DEVELOPMENTS
18.18 OTSUKA AMERICA PHARMACEUTICAL, INC
18.18.1 COMPANY SNAPSHOT
18.18.2 PRODUCT PORTFOLIO
18.18.3 RECENT DEVELOPMENTS
18.19 SANOFI
18.19.1 COMPANY SNAPSHOT
18.19.2 REVENUE ANALYSIS
18.19.3 PRODUCT PORTFOLIO
18.19.4 RECENT DEVELOPMENT
18.2 VIATRIS INC.
18.20.1 COMPANY SNAPSHOT
18.20.2 REVENUE ANALYSIS
18.20.3 PRODUCT PORTFOLIO
18.20.4 RECENT DEVELOPMENT
19 QUESTIONNAIRE
20 RELATED REPORTS
표 목록
TABLE 1 PIPELINE LYOPHILIZED INJECTABLE DRUGS
TABLE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 3 MIDDLE EAST AND AFRICA VIALS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 4 MIDDLE EAST AND AFRICA DUAL-CHAMBER SYRINGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 5 MIDDLE EAST AND AFRICA DUAL-CHAMBER CARTRIDGES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 6 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 9 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 10 MIDDLE EAST AND AFRICA ANTI-INFECTIVE’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 11 MIDDLE EAST AND AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 12 MIDDLE EAST AND AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 13 MIDDLE EAST AND AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 14 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 15 MIDDLE EAST AND AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 16 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 17 MIDDLE EAST AND AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 18 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 19 MIDDLE EAST AND AFRICA PROTON PUMP INHIBITORS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 20 MIDDLE EAST AND AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 21 MIDDLE EAST AND AFRICA ANESTHETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 22 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 23 MIDDLE EAST AND AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 24 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 25 MIDDLE EAST AND AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 26 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 27 MIDDLE EAST AND AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 28 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 30 MIDDLE EAST AND AFRICA POWDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 31 MIDDLE EAST AND AFRICA LIQUID IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 33 MIDDLE EAST AND AFRICA ONCOLOGY IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 34 MIDDLE EAST AND AFRICA AUTOIMMUNE DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 35 MIDDLE EAST AND AFRICA HORMONAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 36 MIDDLE EAST AND AFRICA RESPIRATORY DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 37 MIDDLE EAST AND AFRICA GASTROINTESTINAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 38 MIDDLE EAST AND AFRICA DERMATOLOGICAL DISORDERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 39 MIDDLE EAST AND AFRICA OPHTHALMIC DISEASES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 40 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 42 MIDDLE EAST AND AFRICA INTRAVENOUS/INFUSION IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 43 MIDDLE EAST AND AFRICA INTRAMUSCULAR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 44 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 45 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 46 MIDDLE EAST AND AFRICA HOSPITAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 47 MIDDLE EAST AND AFRICA CLINICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 48 MIDDLE EAST AND AFRICA HOME HEALTHCARE IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 49 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 50 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 51 MIDDLE EAST AND AFRICA DIRECT TENDER IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 52 MIDDLE EAST AND AFRICA RETAIL SALES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 53 MIDDLE EAST AND AFRICA OTHERS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY REGION, 2019-2028 (USD MILLION)
TABLE 54 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY COUNTRY, 2019-2028 (USD MILLION)
TABLE 55 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 56 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 57 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 58 MIDDLE EAST & AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 59 MIDDLE EAST & AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 60 MIDDLE EAST & AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 61 MIDDLE EAST & AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 62 MIDDLE EAST & AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 63 MIDDLE EAST & AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 64 MIDDLE EAST & AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 65 MIDDLE EAST & AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 66 MIDDLE EAST & AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 67 MIDDLE EAST & AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 68 MIDDLE EAST & AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 69 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 70 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 71 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 72 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 73 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 74 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 75 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 76 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 77 SOUTH AFRICA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 78 SOUTH AFRICA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 79 SOUTH AFRICA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 80 SOUTH AFRICA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 81 SOUTH AFRICA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 82 SOUTH AFRICA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 83 SOUTH AFRICA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 84 SOUTH AFRICA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 85 SOUTH AFRICA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 86 SOUTH AFRICA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 87 SOUTH AFRICA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 88 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 89 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 90 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 91 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 92 SOUTH AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 93 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 94 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 95 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 96 SAUDI ARABIA ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 97 SAUDI ARABIA ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 98 SAUDI ARABIA ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 99 SAUDI ARABIA ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 100 SAUDI ARABIA ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 101 SAUDI ARABIA DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 102 SAUDI ARABIA PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 103 SAUDI ARABIA ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 104 SAUDI ARABIA ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 105 SAUDI ARABIA NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 106 SAUDI ARABIA CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 107 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 108 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 109 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 110 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 111 SAUDI ARABIA LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 112 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 113 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 114 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 115 U.A.E. ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 116 U.A.E. ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 117 U.A.E. ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 118 U.A.E. ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 119 U.A.E. ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 120 U.A.E. DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 121 U.A.E. PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 122 U.A.E. ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 123 U.A.E. ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 124 U.A.E. NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 125 U.A.E. CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 126 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 127 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 128 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 129 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 130 U.A.E. LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 131 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 132 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 133 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 134 EGYPT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 135 EGYPT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 136 EGYPT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 137 EGYPT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 138 EGYPT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 139 EGYPT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 140 EGYPT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 141 EGYPT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 142 EGYPT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 143 EGYPT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 144 EGYPT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 145 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 146 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 147 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 148 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 149 EGYPT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 150 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 151 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 152 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 153 KUWAIT ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 154 KUWAIT ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 155 KUWAIT ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 156 KUWAIT ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 157 KUWAIT ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 158 KUWAIT DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 159 KUWAIT PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 160 KUWAIT ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 161 KUWAIT ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 162 KUWAIT NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 163 KUWAIT CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 164 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 165 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 166 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 167 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 168 KUWAIT LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 169 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
TABLE 170 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 171 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (UNITS)
TABLE 172 ISRAEL ANTI-INFECTIVES IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 173 ISRAEL ANTIBIOTICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 174 ISRAEL ANTIFUNGAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 175 ISRAEL ANTIVIRAL IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 176 ISRAEL ANTINEOPLASTIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 177 ISRAEL DIURETICS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 178 ISRAEL PROTON PUMP INHIBITOR IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 179 ISRAEL ANESTHETIC IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 180 ISRAEL ANTICOAGULANT IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 181 ISRAEL NSAID’S IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 182 ISRAEL CORTICOSTEROIDS IN LYOPHILIZED INJECTABLE DRUGS MARKET, BY DRUG CLASS, 2019-2028 (USD MILLION)
TABLE 183 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY FORM, 2019-2028 (USD MILLION)
TABLE 184 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY INDICATION, 2019-2028 (USD MILLION)
TABLE 185 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2019-2028 (USD MILLION)
TABLE 186 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY END USER, 2019-2028 (USD MILLION)
TABLE 187 ISRAEL LYOPHILIZED INJECTABLE DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2019-2028 (USD MILLION)
TABLE 188 REST OF MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET, BY PACKAGING, 2019-2028 (USD MILLION)
그림 목록
FIGURE 1 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 2 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DATA TRIANGULATION
FIGURE 3 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DROC ANALYSIS
FIGURE 4 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MIDDLE EAST AND AFRICA VS. REGIONAL MARKET ANALYSIS
FIGURE 5 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY RESEARCH ANALYSIS
FIGURE 6 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MULTIVARIATE MODELLING
FIGURE 7 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: INTERVIEW DEMOGRAPHICS
FIGURE 8 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: DBMR MARKET POSITION GRID
FIGURE 9 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: VENDOR SHARE ANALYSIS
FIGURE 10 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: MARKET END USER COVERAGE GRID
FIGURE 11 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SEGMENTATION
FIGURE 12 RISE IN CHRONIC HEALTH CONDITIONS IS EXPECTED TO DRIVE THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN THE FORECAST PERIOD OF 2021 TO 2028
FIGURE 13 VIALS SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET IN 2021 & 2028
FIGURE 14 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET
FIGURE 15 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2020
FIGURE 16 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, 2021-2028 (USD MILLION)
FIGURE 17 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, CAGR (2021-2028)
FIGURE 18 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING, LIFELINE CURVE
FIGURE 19 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2020
FIGURE 20 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, 2021-2028 (USD MILLION)
FIGURE 21 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, CAGR (2021-2028)
FIGURE 22 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DRUG CLASS, LIFELINE CURVE
FIGURE 23 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2020
FIGURE 24 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, 2021-2028 (USD MILLION)
FIGURE 25 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, CAGR (2021-2028)
FIGURE 26 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY FORM, LIFELINE CURVE
FIGURE 27 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2020
FIGURE 28 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, 2021-2028 (USD MILLION)
FIGURE 29 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, CAGR (2021-2028)
FIGURE 30 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY INDICATION, LIFELINE CURVE
FIGURE 31 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2020
FIGURE 32 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, 2021-2028 (USD MILLION)
FIGURE 33 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2021-2028)
FIGURE 34 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE
FIGURE 35 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2020
FIGURE 36 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, 2021-2028 (USD MILLION)
FIGURE 37 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, CAGR (2021-2028)
FIGURE 38 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY END USER, LIFELINE CURVE
FIGURE 39 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2020
FIGURE 40 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, 2021-2028 (USD MILLION)
FIGURE 41 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, CAGR (2021-2028)
FIGURE 42 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE
FIGURE 43 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: SNAPSHOT (2020)
FIGURE 44 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020)
FIGURE 45 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2021 & 2028)
FIGURE 46 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY COUNTRY (2020 & 2028)
FIGURE 47 MIDDLE EAST & AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: BY PACKAGING (2021-2028)
FIGURE 48 MIDDLE EAST AND AFRICA LYOPHILIZED INJECTABLE DRUGS MARKET: COMPANY SHARE 2020 (%)
연구 방법론
데이터 수집 및 기준 연도 분석은 대규모 샘플 크기의 데이터 수집 모듈을 사용하여 수행됩니다. 이 단계에는 다양한 소스와 전략을 통해 시장 정보 또는 관련 데이터를 얻는 것이 포함됩니다. 여기에는 과거에 수집한 모든 데이터를 미리 검토하고 계획하는 것이 포함됩니다. 또한 다양한 정보 소스에서 발견되는 정보 불일치를 검토하는 것도 포함됩니다. 시장 데이터는 시장 통계 및 일관된 모델을 사용하여 분석하고 추정합니다. 또한 시장 점유율 분석 및 주요 추세 분석은 시장 보고서의 주요 성공 요인입니다. 자세한 내용은 분석가에게 전화를 요청하거나 문의 사항을 드롭하세요.
DBMR 연구팀에서 사용하는 주요 연구 방법론은 데이터 마이닝, 시장에 대한 데이터 변수의 영향 분석 및 주요(산업 전문가) 검증을 포함하는 데이터 삼각 측량입니다. 데이터 모델에는 공급업체 포지셔닝 그리드, 시장 타임라인 분석, 시장 개요 및 가이드, 회사 포지셔닝 그리드, 특허 분석, 가격 분석, 회사 시장 점유율 분석, 측정 기준, 글로벌 대 지역 및 공급업체 점유율 분석이 포함됩니다. 연구 방법론에 대해 자세히 알아보려면 문의를 통해 업계 전문가에게 문의하세요.
사용자 정의 가능
Data Bridge Market Research는 고급 형성 연구 분야의 선두 주자입니다. 저희는 기존 및 신규 고객에게 목표에 맞는 데이터와 분석을 제공하는 데 자부심을 느낍니다. 보고서는 추가 국가에 대한 시장 이해(국가 목록 요청), 임상 시험 결과 데이터, 문헌 검토, 재생 시장 및 제품 기반 분석을 포함하도록 사용자 정의할 수 있습니다. 기술 기반 분석에서 시장 포트폴리오 전략에 이르기까지 타겟 경쟁업체의 시장 분석을 분석할 수 있습니다. 귀하가 원하는 형식과 데이터 스타일로 필요한 만큼 많은 경쟁자를 추가할 수 있습니다. 저희 분석가 팀은 또한 원시 엑셀 파일 피벗 테이블(팩트북)로 데이터를 제공하거나 보고서에서 사용 가능한 데이터 세트에서 프레젠테이션을 만드는 데 도움을 줄 수 있습니다.